IR-Med’s PressureSafe Noninvasive Wound Care Device to be Demonstrated at Northwell Health’s 10th Annual Shining the Light on Wound Care Symposium
Rosh Pina, Israel, May 19, 2023 (GLOBE NEWSWIRE) — IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven spectrographic analysis technology platform to address significant healthcare needs, announced today it will exhibit and conduct live demonstrations of its PressureSafe wound care device at Northwell Health’s 10th Annual Shining the Light on Wound Care Symposium on May 19, 2023 at the TWA Hotel at JFK International Airport in New York.
Related news for (IRME)
- IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment
- IR-MED CEO Issues Letter to Shareholders: Expanding Our Platform and Presenting New Clinical Data from Israel and the U.S.
- IR-MED Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers
- IR-MED’s PressureSafe™ Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel’s Largest HMO
- IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries